The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'August 2020'. If you still can't find what you are looking for, try using the search box.
Sandwich, Kent, UK: Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, has been awarded £2.5m towards accelerated delivery of its Incubator facility by the South East Local Enterprise Partnership (SELEP). The grant, which comes from SELEP’s £85m share of the Government’s new Getting Building Fund, will be used to create flexible laboratory, write-up and office space for innovative SMEs. Discovery Park’s investors are committing £3m to this development, which is expected to be completed by the middle of next year.
A masterplan has been created for the Incubator space and initial design works completed. The 50,000 sq ft of laboratory and write-up space will be created on two floors of the East Block of the Park’s Building 500. The new Incubator facility will be suitable for all types of start-ups and early stage companies, including drug discovery, cell and gene therapy, digital health, manufacturing a ...
Read the rest of entry »
Cyprotex, an Evotec company, are hosting a series of webinars on the topic of drug transporters with speakers from Novartis, Genentech and Cyprotex.
These will take place on each Wednesday in September.
Learn more and reserve your seat: https://hubs.ly/H0tcQ2X0
Oxford, UK: VivoPlex Group Ltd, which is transforming fertility treatment and women’s health via intra-uterine sensing, has raised £3.9m in its Clinical Stage financing round. The funds, which were raised in two tranches, will be used to complete the first clinical feasibility study of its wireless battery-free uterine sensor system. The study is expected to generate key clinical data to support European approval (CE marking) for the company’s first product.
The Future Fund participated in the second tranche of the fundraising alongside other investors, unlocking matched financing and helping to drive the business forward towards commercialisation. Developed by the Government and delivered by the British Business Bank, the Future Fund supports high potential innovative businesses in the UK currently affected by Covid-19.
In line with other medical device and pharmaceutical companies, the clinical feasibility study will start as soon as practicabl ...
Oxford, UK: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new Development, Manufacture & License Agreement (“DMLA”) with Beam Therapeutics Inc. (“Beam”) (Nasdaq: BEAM), a Cambridge, Mass.-based biotechnology company developing precision genetic medicines through the use of base editing. The DMLA grants Beam a non-exclusive license to Oxford Biomedica’s LentiVector® platform for its application in next generation CAR-T programmes in oncology and puts in place a three year Clinical Supply Agreement.
Under the terms of the DMLA, Oxford Biomedica will receive an undisclosed upfront payment, as well as payments related to development and manufacturing of lentiviral vectors for use in clinical trials, and certain development and regulatory milestones for products sold by Beam that utilise Oxford Biomedica’s LentiVector® platfo ...
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.